Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 402,082 shares, a decline of 95.1% from the April 15th total of 8,149,924 shares. Based on an average daily trading volume, of 41,896 shares, the short-interest ratio is currently 9.6 days. Currently, 5.3% of the shares of the stock are short sold.
NYSEAMERICAN NAVB opened at $1.43 on Wednesday. Navidea Biopharmaceuticals has a 1-year low of $1.21 and a 1-year high of $7.40.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter. The firm had revenue of $0.14 million for the quarter.
An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. BlackRock Inc. increased its holdings in Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 0.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,498,050 shares of the biopharmaceutical company’s stock after buying an additional 6,975 shares during the period. BlackRock Inc. owned 24.89% of Navidea Biopharmaceuticals worth $345,000 as of its most recent filing with the Securities and Exchange Commission.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Featured Story: How mutual funds make money
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.